Coalition of Rheumatology Educators
First In Specialist-Focused Rheumatology Continuing Education

Since 2007, the Coalition of Rheumatology Educators (CORE) remains the leader in live regional programming for rheumatology specialists and is fast becoming the preferred educational resource destination for web and mobile-based learning.
What Would You Do?

Treat patients with rheumatic disease to remission in our challenging patient cases!

Amy is a 31-year-old female who presents to her primary care physician with an 8-week history of joint pain and stiffness
Join Us At A CORE Regional Workshop Near You.

The Coalition of Rheumatology Educators (CORE) brings to you renowned rheumatology thought leaders for state-of-the-art presentations and in-depth peer discussions.  Click here to see who will be presenting in a city near you in May
CME Post-test Available for SLE Dinner Symposium

Take your post-test and earn CME for the talk by Michelle Petri, MD, MPH, Meenakshi Jolly, MD, MS, and Daniel J. Wallace, MD, FACP, FACR, for an interactive case-based discussion. Click here.

1
2
3
4

Live Events

more
Regional Meeting: Treating to Target in SLE: Translating Patient Assessment and Novel Pharmacotherapies to Improved Outcomes (CME, CNE)
Regional Meeting: CME Dinner Workshop Series: Patient-Centric Approaches for Achieving Remission in Rheumatic Disease (CME)

Online Courses

more
On-Demand Webcast: Advancing the RA Armamentarium with Emerging Therapies (CME)
Publication: Aggressively Pursuing Remission in RA: Where Will Emerging Therapies Fit into the Treatment Armamentarium? (CME)
Publication: Applying Scientific Measurement of Disease Activity in Clinical Rheumatology (AANP, CME, CNE)
Case Study: Case 1: JW is a 31-year-old woman who presents with an 8-week-history of joint pain and stiffness. Her initial lab results indicate an RF of >500 and an anti-CCP of >100 (CME)
Case Study: Case 2: ML is a 35-year-old woman whose RA regimen was halted when she was recently hospitalized with pulmonary infection. Her respiratory symptoms have resolved, but ML’s RA symptoms have flared dramatically. (CME)
Case Study: Case 3: CB is a 38-year-old man, employed as a carpenter, who presents with a 2-month history of pain in multiple joints that has caused difficulty in using tools and carrying lumber at work. CB has a family history of RA, and his mother was HLADR4+. (CME)
Case Study: Case 4: SB is a 52-year-old woman with a 2-year history of increasing polyarthritis. She presents for evaluation after her PCP-prescribed regimen of TNFI and naproxen becomes increasingly ineffective. (CME)

News

More
05/16/2012
Nanoparticle Drug Delivery May Influence Immune Response in RA

Reported in The Journal of Immunology, Georgia Health Sciences University researchers have found an association between the DNA nanoparticle drug delivery technique and an increased expression of an enzyme that calms the immune response in animals. This finding suggests therapeutic value of this technique for autoimmune diseases, including rheumatoid arthritis, through inflammation reduction. 

Read More
05/15/2012
New Compounds May Help Inhibit Arthritis and Other Inflammatory Conditions

A new study from Scripps Research Institute has identified the first compound able to block PRMT1, an enzyme associated with inflammatory conditions, such as arthritis. The research may facilitate the development of pharmacologic treatments for inflammatory conditions and cancers.

Read More
05/14/2012
New Guidelines Issued for Osteoarthritis Therapy

The American College of Rheumatology has issued new guidelines that recommend a balanced management strategy of therapeutic agents and nonpharmacologic interventions for patients with osteoarthritis.

Read More